Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Alkermes Plc (ALKS)  
$24.14 0.35 (1.43%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 183,678,000
Market Cap: 4.43(B)
Last Volume: 775,760 Avg Vol: 773,615
52 Week Range: $23.37 - $33.63
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Delivery

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  581
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 35,000
Total Buy Value $0 $0 $0 $815,735
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 15,666 15,666 48,238 146,962
Total Sell Value $454,291 $454,291 $1,411,373 $4,368,837
Total People Sold 3 3 3 5
Total Sell Transactions 3 3 6 9
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 2018
  Page 19 of 81  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-03-01 4 D $20.84 $27,571 D/D (1,323) 69,845     -
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-03-01 4 OE $0.00 $0 D/D 4,500 71,168     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2020-03-01 4 OE $0.00 $0 D/D 4,500 201,822     -
   Wysenski Nancy Director   •       •      –    2020-02-24 4 B $19.65 $136,371 I/I 6,940 11,242 2.1 -1%     
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2020-02-21 4 D $20.24 $291,173 D/D (14,386) 749,364     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 32,400 763,750     -
   Brown Iain Michael SVP Finance & CAO, Alks Inc.   •       •      –    2020-02-21 4 D $20.24 $28,154 D/D (1,391) 36,993     -
   Brown Iain Michael SVP Finance & CAO, Alks Inc.   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 4,800 38,384     -
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-02-21 4 D $20.24 $34,651 D/D (1,712) 66,668     -
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 5,825 68,380     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2020-02-21 4 D $20.24 $40,561 D/D (2,004) 13,951     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 6,875 15,955     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2020-02-21 4 D $20.24 $40,804 D/D (2,016) 57,346     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 6,875 59,362     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2020-02-21 4 OE $0.00 $0 D/D 5,825 197,322     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2020-02-17 4 D $17.77 $69,054 D/D (3,886) 731,350     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2020-02-17 4 OE $0.00 $0 D/D 8,750 735,236     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2020-02-17 4 D $17.77 $13,612 D/D (766) 52,487     -
   Gaffin David Joseph SVP, CLO, Alkermes, Inc.   •       •      –    2020-02-17 4 OE $0.00 $0 D/D 2,500 53,253     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2020-02-17 4 OE $0.00 $0 D/D 3,000 191,497     -
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-02-17 4 D $17.77 $16,064 D/D (904) 62,555     -
   Frates James M SVP, Alks Inc; CFO ALKS   •       •      –    2020-02-17 4 OE $0.00 $0 D/D 3,000 63,459     -
   Brown Iain Michael SVP Finance & CAO, Alks Inc.   •       •      –    2020-02-17 4 D $17.77 $15,424 D/D (868) 33,584     -
   Brown Iain Michael SVP Finance & CAO, Alks Inc.   •       •      –    2020-02-17 4 OE $0.00 $0 D/D 2,500 34,452     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2020-02-16 4 D $17.77 $143,439 D/D (8,072) 726,486     -

  2018 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 19 of 81
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed